Aethlon CEO to Present at Biotech-To-Biodefense Conference.

SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD) announced that its Chairman and CEO, James A. Joyce will be a featured presenter at the Biotech-To-Biodefense Conference being held today at the Estancia La Jolla Hotel & Spa in La Jolla, California. The Biotech-To-Biodefense Conference is a national conference featuring the nation's leading experts on legislation and federal funding addressing emerging threats including both pandemic-related and biodefense-related procurements. Representatives from bio-pharma companies, research institutions, and government who have participated in awarded and pending BioShield and pandemic contracts will provide insights into their experience and views on the path ahead. This conference draws attendees from throughout the United States.

About Aethlon Medical

Aethlon Medical is pioneering the development of immunotherapeutic devices able to mimic the immune response of clearing viruses and viral toxins from circulation. The Company's lead product, the Hemopurifier(TM), converges the established principals of hemodialysis and affinity chromatography with the discovery of compounds that effectively adhere to the surface of a multiple envelope viruses. The Hemopurifier(TM)is targeted to treat acute and chronic infectious diseases, including, drug and vaccine resistant Biological Weapons, the Human Immunodeficiency Virus (HIV), and the Hepatitis-C Virus (HCV). The Company has an experienced management team, which receives support and guidance from globally recognized science and regulatory advisors representing the infectious disease, biowarfare, and dialysis industries. More information on Aethlon Medical and the Hemopurifier(TM) technology can be found at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.